Key points are not available for this paper at this time.
Two groups of patients with thoracic oesophageal cancer were treated with a 22 MeV betatron. 54 patients received a dose of 6,900 rads in six weeks within the whole of the thoracic oesophagus. The average survival was 10·9 months and two patients were living five years after treatment. 61 patients received 5,200 rads within the whole of the thoracic oesophagus, and for these patients with a cancer of a length less than a fourth of the whole oesophagus, a complement of 3,500 rads to the tumour residue. The average survival was 11·4 months; one patient was living five years after treatment.
Pierquin et al. (Tue,) studied this question.